UY28875A1 - Tratamiento de la hemorragia de disrupción en regímenes anticonceptivos extendidos. - Google Patents

Tratamiento de la hemorragia de disrupción en regímenes anticonceptivos extendidos.

Info

Publication number
UY28875A1
UY28875A1 UY28875A UY28875A UY28875A1 UY 28875 A1 UY28875 A1 UY 28875A1 UY 28875 A UY28875 A UY 28875A UY 28875 A UY28875 A UY 28875A UY 28875 A1 UY28875 A1 UY 28875A1
Authority
UY
Uruguay
Prior art keywords
hemorragy
conceptive
regimes
disruption
treatment
Prior art date
Application number
UY28875A
Other languages
English (en)
Spanish (es)
Inventor
Andreas Sachse
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35056905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY28875(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of UY28875A1 publication Critical patent/UY28875A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Steroid Compounds (AREA)
UY28875A 2004-04-30 2005-04-27 Tratamiento de la hemorragia de disrupción en regímenes anticonceptivos extendidos. UY28875A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US56644304P 2004-04-30 2004-04-30
US57502404P 2004-05-28 2004-05-28
US57719904P 2004-06-07 2004-06-07
US63838004P 2004-12-27 2004-12-27
US66006805P 2005-03-10 2005-03-10

Publications (1)

Publication Number Publication Date
UY28875A1 true UY28875A1 (es) 2005-11-30

Family

ID=35056905

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28875A UY28875A1 (es) 2004-04-30 2005-04-27 Tratamiento de la hemorragia de disrupción en regímenes anticonceptivos extendidos.

Country Status (29)

Country Link
US (3) US8163721B2 (OSRAM)
EP (1) EP1747001B1 (OSRAM)
JP (4) JP2007535519A (OSRAM)
KR (4) KR20160150113A (OSRAM)
CN (1) CN103127156A (OSRAM)
AR (1) AR048722A1 (OSRAM)
AU (1) AU2005237255B2 (OSRAM)
BR (1) BRPI0510493A (OSRAM)
CA (1) CA2562296A1 (OSRAM)
CR (1) CR8709A (OSRAM)
DK (1) DK1747001T3 (OSRAM)
EA (2) EA031227B1 (OSRAM)
EC (1) ECSP066999A (OSRAM)
ES (1) ES2704999T3 (OSRAM)
HU (1) HUE041475T2 (OSRAM)
IL (1) IL178458A (OSRAM)
LT (1) LT1747001T (OSRAM)
MX (1) MXPA06012567A (OSRAM)
MY (1) MY151322A (OSRAM)
NO (1) NO341685B1 (OSRAM)
NZ (1) NZ586107A (OSRAM)
PA (1) PA8631801A1 (OSRAM)
PE (1) PE20060467A1 (OSRAM)
SG (2) SG10201701904TA (OSRAM)
SI (1) SI1747001T1 (OSRAM)
SV (1) SV2006002100A (OSRAM)
TW (1) TWI374735B (OSRAM)
UY (1) UY28875A1 (OSRAM)
WO (1) WO2005105103A2 (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US20070088010A1 (en) * 2005-10-17 2007-04-19 Doris Huebler Method of making a single-stage pharmaceutical preparation for oral therapy of dysfunctional uterine bleeding, containing ethinyl estradiol and dienogest
EP1977752A1 (de) * 2007-03-01 2008-10-08 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zubereitung zur Verminderung der Endometriose
DE102007011105A1 (de) * 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
WO2010033188A2 (en) * 2008-09-16 2010-03-25 Playtex Products, Llc. Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administering same
CA2740004A1 (en) 2008-10-08 2010-04-15 Agile Therapeutics, Inc. Transdermal delivery
CA2740002C (en) 2008-10-08 2016-11-01 Agile Therapeutics, Inc. Transdermal delivery
WO2010042612A1 (en) 2008-10-08 2010-04-15 Agile Therapeutics, Inc. Transdermal delivery
US9198920B2 (en) 2009-03-27 2015-12-01 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
HUE054589T2 (hu) 2015-06-18 2021-09-28 Estetra Sprl Szájban diszpergálódó esztetrol tartalmú tabletta
JP6866560B2 (ja) 2015-06-18 2021-04-28 エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ エステトロール成分を含有する口腔内崩壊性投与単位
MD3310346T2 (ro) 2015-06-18 2021-06-30 Estetra Sprl Comprimată orodispersabilă ce conține estetrol
MY195019A (en) 2015-06-18 2023-01-03 Estetra Sprl Orodispersible dosage unit containing an estetrol component
MX389310B (es) * 2015-06-23 2025-03-20 Laboratorios Leon Farma Sa Anticonceptivos a base de drospirenona para paciente femenina afectada con exceso de peso.
KR102712911B1 (ko) 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
JP7043503B2 (ja) 2016-09-30 2022-03-29 ミオバント サイエンシズ ゲーエムベーハー 子宮筋腫及び子宮内膜症を治療する方法
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
US12138270B2 (en) 2021-09-07 2024-11-12 Millicent Pharma Limited Contraceptive regimen including reduced level of estrogen

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244096A (en) 1988-04-22 1993-09-14 Stoner Fred L Preventive treatment kit against sexually transmitted disease
AU3473193A (en) 1992-01-17 1993-08-03 Procter & Gamble Company, The Treatment for atherosclerosis
DE4344462C2 (de) 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
US5552394A (en) 1994-07-22 1996-09-03 The Medical College Of Hampton Roads Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
AU726091B2 (en) * 1996-07-26 2000-11-02 Wyeth Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen
US6451778B1 (en) 1996-07-26 2002-09-17 Wyeth Oral contraceptive
US5842441A (en) 1996-08-26 1998-12-01 Pharmalett Denmark A/S Medicated and individualized treatment shampoo for dermatological disturbances of companion animals
US5898032A (en) 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
ES2319750T3 (es) 1999-08-31 2009-05-12 Bayer Schering Pharma Aktiengesellschaft Composicion farmaceutica que comprende etinilestradiol y drospirenona para usar como anticonceptivo.
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
CO5271709A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
US6653298B2 (en) * 2000-01-14 2003-11-25 Sterix Limited Composition
DE10045380A1 (de) * 2000-09-14 2002-04-04 Schering Ag Verfahren zur Kontrazeption und dessen Darreichungsform
TWI303990B (en) 2000-10-17 2008-12-11 Pfizer Prod Inc New use of estrogen agonists/antagonists for improving vascular health
US20020193356A1 (en) * 2001-05-23 2002-12-19 Van Beek Agatha Antonia Magdalena Means and method for hormonal contraception
US20030018018A1 (en) 2001-07-10 2003-01-23 Medical College Of Hampton Roads Ultra low dose oral contraceptives with sustained efficacy and induced amenorrhea
MY151322A (en) * 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
US8501720B2 (en) 2004-07-30 2013-08-06 Bayer Pharma AG Method for treatment of dysmenorrhea

Also Published As

Publication number Publication date
AU2005237255B2 (en) 2011-07-07
EA031227B1 (ru) 2018-12-28
JP2015187157A (ja) 2015-10-29
BRPI0510493A (pt) 2007-11-13
PE20060467A1 (es) 2006-06-11
US20050250747A1 (en) 2005-11-10
HUE041475T2 (hu) 2019-05-28
IL178458A (en) 2016-08-31
KR101812160B1 (ko) 2017-12-27
KR20160150113A (ko) 2016-12-28
NO20065499L (no) 2006-11-29
DK1747001T3 (en) 2019-02-04
JP2007535519A (ja) 2007-12-06
SI1747001T1 (sl) 2019-02-28
KR20150058555A (ko) 2015-05-28
CR8709A (es) 2007-08-28
CA2562296A1 (en) 2005-11-10
SG10201701904TA (en) 2017-05-30
NZ586107A (en) 2012-05-25
NO341685B1 (no) 2017-12-18
WO2005105103A3 (en) 2006-09-08
PA8631801A1 (es) 2006-11-09
JP2013018787A (ja) 2013-01-31
MY151322A (en) 2014-05-15
AR048722A1 (es) 2006-05-17
CN103127156A (zh) 2013-06-05
JP6134491B2 (ja) 2017-05-24
EP1747001A2 (en) 2007-01-31
EA016625B1 (ru) 2012-06-29
TW200603781A (en) 2006-02-01
JP6153967B2 (ja) 2017-06-28
AU2005237255A1 (en) 2005-11-10
JP2017048253A (ja) 2017-03-09
LT1747001T (lt) 2019-01-25
IL178458A0 (en) 2008-04-13
WO2005105103A2 (en) 2005-11-10
KR20070004919A (ko) 2007-01-09
SG152288A1 (en) 2009-05-29
ES2704999T3 (es) 2019-03-21
EA201200377A8 (ru) 2018-01-31
US8163721B2 (en) 2012-04-24
US20150174142A1 (en) 2015-06-25
ECSP066999A (es) 2006-12-29
KR20130022425A (ko) 2013-03-06
US20120202779A1 (en) 2012-08-09
SV2006002100A (es) 2006-02-15
EA201200377A1 (ru) 2012-08-30
EP1747001B1 (en) 2018-10-10
TWI374735B (en) 2012-10-21
EA200601908A1 (ru) 2007-04-27
MXPA06012567A (es) 2006-12-15

Similar Documents

Publication Publication Date Title
UY28875A1 (es) Tratamiento de la hemorragia de disrupción en regímenes anticonceptivos extendidos.
ECSP088097A (es) Nuevos regímenes para dispositivos de administración controlada de fármacos para anticoncepción
ECSP056229A (es) Una composición farmacéutica que comprende formas polimórficas de 3-(4-amino-1-oxo-1.3 dyhidro-isoindol-2-il)-piperidina-2,6-diona para el tratamiento y manejo de cánceres
AR033555A1 (es) Producto para el tratamiento del carcinoma de receptor de estrogeno positivo, y uso de dicho producto para preparar medicamentos
MX2009003992A (es) Empaque para articulos absorbentes desechables y estuche del empaque y articulos absorbentes desechables.
CR7610A (es) Uso de derivados de thio-oxindol en el tratamiento de condiciones realcionadas con la hormona
CL2007001961A1 (es) Composicion farmaceutica que contiene a) 2,0 mg de dienogest y 0,015 mg de etinilestradiol y (6s)-5-metil-tetrahidrofolato y uno o mas excipiente/vehiculos; kit; uso para la anticoncepcion femeneina y reducir el riesgo d malformaciones congenitas debidas a la falta de folato en el embarazo.
AR040130A1 (es) Esteres de etonogestrel, su uso como anticopceptivo y para el tratamiento de desordenes ginecologicos
BRPI0514144A (pt) dispositivo de administração de produto farmacêutico
BRPI0509053A (pt) composição farmacêutica anidra e uso de um agente siliconado e de uma composição
AR030140A1 (es) Composiciones derivadas de la 2-piridinamina y metodos relacionados
CL2008000999A1 (es) Composicion farmaceutica que comprende drospirenona y 17beta estradiol; kit farmaceutico que comprende a dicha composicion, util para terapia hormonal y contracepcion en mujeres.
AR043013A1 (es) Composicion farmaceutica destinada al tratamiento de la endometriosis
CU20060204A7 (es) Tratamiento de la hemorragia de disrupción en regímenes anticonceptivos extendidos
CL2011000252A1 (es) Uso de estriol para preparar un medicamento util en la prevencion y/o el tratamiento de atrofia urogenital en mujeres.
SI1869185T1 (sl) Konjugat ki obsega protein P za zdravljenje raka
UY29925A1 (es) Derivados de 9-cloro-15-desoxiprostaglandina, procesos para su preparación y su uso como medicamento.
BRPI0513825A (pt) combinações de epotilona
UY28762A1 (es) Nuevos compuestos
CL2008001147A1 (es) Combinacion farmaceutica que comprende 11b-(4-acetilfenil)-17b-hidroxi-17 (1,1,2,2,2-pentafluoroetil) estra-4,9-dien-3-ona junto con al menos un antiestrogeno no esteroidal puro; y uso para la profilaxis o el tratamientodel cancer mediado por brca1 o brca2.
CL2008001148A1 (es) Combinacion farmaceutica que comprende un antagonista del receptor de progesterona 11beta-(4-acetilfenil)-17beta-hidroxi-17alfa-(1,1,2,2,2-pentafluoroetil)-estra-4,9-dien-3-ona y un antiestrogeno; y su uso para el tratameinto del cancer de mama.
BRPI0510906A (pt) composição farmacêutica tópica, composição para administração tópica e seu uso
AR049220A1 (es) Uso de 7-ter-butoxiiminometilcamptotecina en la preparacion de un medicamento util para el tratamiento de neoplasmas uterinos
AR048355A1 (es) Asociacion entre un compuesto heterociclico y un agente antioxidante y las composiciones farmaceuticas que los contienen
AR034810A1 (es) Composicion farmaceutica para la administracion por via nasal de estradiol y de noretisterona

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20170321

VENC Patent expired

Effective date: 20250427